Clinical, immune cell, and genetic features predicting survival and long-term response to first-line chemo-immunotherapy treatment for non-small cell lung cancer by Liling Huang, Haohua Zhu, Liyuan Dai, Yu Feng, Xinrui Chen, Zucheng Xie, Xingsheng Hu, Yutao Liu, Xuezhi Hao, Lin Lin, Hongyu Wang, Shengyu Zhou, Jiarui Yao, Le Tang, Xiaohong Han, Yuankai Shi

“…LTR was defined as progression-free survival (PFS) exceeding 24 months, while non-responders had a PFS of less than 6 months. …”
Get full text